By Adam Leitenberger
The FDA and the Federal Trade Commission (FTC) announced they will take further action to stem anticompetitive practices that are blocking biosimilars from entering the U.S. market. The practices are keeping the costs of these drugs artificially high, the regulators say.
In a joint statement released in early February, the two agencies outlined steps they hope will achieve four key goals established in the FDA Biosimilar Action Plan of 2018 to support more competition